Jörg Felsberg
A5056119087- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Chromatin Remodeling and Cancer
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Meningioma and schwannoma management
- Cancer Cells and Metastasis
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Cancer-related molecular mechanisms research
- Hedgehog Signaling Pathway Studies
- Protein Tyrosine Phosphatases
- ATP Synthase and ATPases Research
- Ubiquitin and proteasome pathways
- Medical Imaging Techniques and Applications
- Congenital heart defects research
- Protein Degradation and Inhibitors
- Neuroblastoma Research and Treatments
- Advanced Electron Microscopy Techniques and Applications
- Microtubule and mitosis dynamics
- Nanoplatforms for cancer theranostics
Heinrich Heine University Düsseldorf
2016-2025
Düsseldorf University Hospital
2010-2025
Deutschen Konsortium für Translationale Krebsforschung
2016-2024
Agaplesion Bethesda Krankenhaus
2022
University of Zurich
2011-2021
University Hospital of Zurich
2010-2021
German Cancer Research Center
2009-2020
Heidelberg University
2009-2020
University Hospital Heidelberg
2009-2017
University Medical Center
2017
Medulloblastoma is the most common brain tumour in children; using whole-genome sequencing of samples authors show that clinically challenging Group 3 and 4 tumours can be tetraploid, reveal expression first medulloblastoma fusion genes identified. malignant children. Four papers published 2 August 2012 issue Nature use other techniques to produce a detailed picture genetics genomics this condition. Notable findings include identification recurrent mutations not previously implicated...
Purpose The standard of care for anaplastic gliomas is surgery followed by radiotherapy. NOA-04 phase III trial compared efficacy and safety radiotherapy chemotherapy at progression with the reverse sequence in patients newly diagnosed gliomas. Patients Methods (N = 318) were randomly assigned 2:1:1 (A:B1:B2) to receive conventional (arm A); procarbazine, lomustine (CCNU), vincristine (PCV; arm B1); or temozolomide B2) diagnosis. At occurrence unacceptable toxicity disease progression, A...
The prognostic value of genetic alterations characteristic glioblastoma in patients treated according to present standards care is unclear.Three hundred one with were prospectively recruited between October 2004 and December 2006 at the clinical centers German Glioma Network. Two fifty-eight had radiotherapy, 199 temozolomide, 189 both, seven another chemotherapy as initial treatment. tumors investigated for TP53 mutation, p53 immunoreactivity, epidermal growth factor receptor,...
Medulloblastoma is the most common malignant brain tumor in children. Current treatment decisions are based on clinical variables. Novel tumor-derived biomarkers may improve risk stratification of medulloblastoma patients.A model for molecular was proposed from an array-based comparative genomic hybridization (array-CGH) screen (n = 80). Fluorescence situ (FISH) analyses chromosome arms 6q, 17p, and 17q MYC MYCN loci were performed independent validation set 260). Copy number aberrations...
Abstract Epigenetic silencing of the O 6 ‐methylguanine‐DNA methyltransferase ( MGMT ) gene promoter is associated with prolonged survival in glioblastoma patients treated temozolomide (TMZ). We investigated whether recurrence changes methylation status and expression DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 PMS2 pairs primary recurrent glioblastomas 80 patients, including 64 radiotherapy TMZ after first operation. Among tumors, was methylated 31 unmethylated 49 patients. In 71...
O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation identifies a subpopulation of glioblastoma patients with more favorable prognosis and predicts benefit from alkylating agent chemotherapy (CT). Little is known about its prevalence clinical significance in older patients. We studied 233 aged 70 years or (144 males, 89 females, median age: 74 years, range: 70.0-86.6 years), who were prospectively enrolled the German Glioma Network, for MGMT by methylation-specific PCR (MSP)...
Abstract Prognostic factors and standards of care for astrocytoma, isocitrate dehydrogenase (IDH)-mutant, CNS WHO grade 4, remain poorly defined. Here we sought to explore disease characteristics, prognostic markers, outcome in patients with this newly defined tumor type. We determined molecular biomarkers assembled clinical data IDH-mutant astrocytomas confirmed by central pathology review. Patients were identified the German Glioma Network cohort study; additional cohorts 4 tumors...
Current immunotherapies provide limited benefits against T cell-depleted tumors, calling for therapeutic innovation. Using multi-omics integration of cancer patient data, we predict a type I interferon (IFN) response
Abstract Allelic losses on the chromosome arms 1p and 19q have been associated with favorable response to chemotherapy good prognosis in anaplastic oligodendroglioma patients, but molecular mechanisms responsible for this relationship are as yet unknown. The DNA repair enzyme O 6 ‐methylguanine methyltransferase (MGMT) may cause resistance DNA‐alkylating drugs commonly used treatment of oligodendrogliomas other malignant gliomas. We report analysis 52 oligodendroglial tumors MGMT promoter...
Evaluation of toxicity and efficacy an alternating weekly regimen temozolomide administered 1 week on off in patients with recurrent glioma.Ninety adult gliomas accrued one center received chemotherapy at 150 mg/m(2)/d (days through 7 15 21 every 4 weeks) individual dose adjustments according to hematologic toxicity.A total 906 treatment weeks were delivered. Grade hematotoxicity the Common Terminology Criteria for Adverse Events (CTCAE; version 3.0) was observed 24 (2.6%). CTCAE grade...
Silencing of O6-methylguanine-DNA methyltransferase (MGMT) protein expression because MGMT gene promoter hypermethylation is considered to be associated with postoperative chemoradiotherapy benefits in glioblastoma multiforme (GBM) patients. The objective this study was clarify the usability immunohistochemistry (IHC) as a clinical biomarker. We immunostained tissue microarray containing biopsy samples 164 GBM patients from European Organization for Research and Treatment Cancer National...